GlassScriptPhysician profile
Tyula Hale
NPI 1467902619
$2,783.99
in general payments reported to CMS, 2019-2025
15 companies · $1,461 in 2025
The $1,461 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $60.01 · 2024: $1,263 · 2025: $1,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,783.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $833.08 | 2023-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $521.81 | 2024-2025 | Biktarvy, Yeztugo |
| Merck Sharp & Dohme LLC | $198.71 | 2024-2025 | Pifeltro, Capvaxive, Delstrigo |
| Radius Health, INC. | $182.54 | 2025 | Tymlos |
| Amgen INC. | $123.68 | 2024 | Repatha |
| Sk Life Science, INC. | $116.63 | 2025 | Xcopri |
| Ani Pharmaceuticals, INC. | $112.58 | 2025 | Purified Cortrophin Gel |
| Eisai INC. | $109.22 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $99.75 | 2025 | |
| Medicure Pharma INC. | $99.75 | 2025 | Zypitamag |
| Teva Pharmaceuticals USA, INC. | $99.36 | 2024 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $95.25 | 2024 | Rexulti |
| Paratek Pharmaceuticals, INC. | $74.13 | 2024 | Nuzyra |
| Axsome Therapeutics, INC. | $61.51 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $55.99 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyula Hale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.